Central CRF2 receptor antagonism reduces anxiety states during amphetamine withdrawal

Emily D. Reinbold, Jamie L. Scholl, Kathryn M. Oliver, Michael J. Watt, Gina L. Forster

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Increased depressive and anxiety-like behaviors are exhibited by rats and humans during withdrawal from psychostimulants. Anxiety-like behaviors observed during amphetamine withdrawal are mediated by increased expression and activity of corticotropin releasing factor type 2 (CRF2) receptors in the dorsal raphe nucleus (dRN). Anxiety-like behavior of rats during withdrawal can be reversed by CRF2 receptor antagonism in the dRN, but the efficacy of global central CRF2 receptor antagonism is unknown. Rats were treated with amphetamine (2.5mg/kg, ip.) or saline daily for 2 weeks, and were tested for anxiety-like behaviors during withdrawal. Rats undergoing withdrawal showed increased anxiety-like behavior, which was reduced by ventricular infusion of the CRF2 antagonist antisauvagine-30 (ASV 2μg/2μl). Surprisingly, ventricular ASV increased anxiety-like behavior in rats pre-treated with saline, but had an anxiolytic effect in un-treated rats. Western blots were performed to determine whether differences in CRF receptor densities could explain ASV-induced behavioral results. Saline pre-treated rats showed reduced CRF1 receptor expression in the lateral septum compared to amphetamine pre-treated and un-treated rats. Overall, these results suggest that central CRF2 antagonism reduces anxiety states during amphetamine withdrawal, and that behavioral effects may be dependent upon the balance of CRF1 and CRF2 receptor activity in anxiety-related regions.

Original languageEnglish (US)
Pages (from-to)37-43
Number of pages7
JournalNeuroscience Research
Volume89
DOIs
StatePublished - Dec 1 2014

Fingerprint

Amphetamine
Anxiety
Corticotropin-Releasing Hormone
Corticotropin-Releasing Hormone Receptors
CRF receptor type 2
Anti-Anxiety Agents
Western Blotting

Keywords

  • Amygdala
  • Antisauvagine-30
  • Anxiety
  • Corticotropin-releasing factor
  • Lateral septum
  • Stress

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Central CRF2 receptor antagonism reduces anxiety states during amphetamine withdrawal. / Reinbold, Emily D.; Scholl, Jamie L.; Oliver, Kathryn M.; Watt, Michael J.; Forster, Gina L.

In: Neuroscience Research, Vol. 89, 01.12.2014, p. 37-43.

Research output: Contribution to journalArticle

@article{94f3a67544024f6da5dbe29cfa87f859,
title = "Central CRF2 receptor antagonism reduces anxiety states during amphetamine withdrawal",
abstract = "Increased depressive and anxiety-like behaviors are exhibited by rats and humans during withdrawal from psychostimulants. Anxiety-like behaviors observed during amphetamine withdrawal are mediated by increased expression and activity of corticotropin releasing factor type 2 (CRF2) receptors in the dorsal raphe nucleus (dRN). Anxiety-like behavior of rats during withdrawal can be reversed by CRF2 receptor antagonism in the dRN, but the efficacy of global central CRF2 receptor antagonism is unknown. Rats were treated with amphetamine (2.5mg/kg, ip.) or saline daily for 2 weeks, and were tested for anxiety-like behaviors during withdrawal. Rats undergoing withdrawal showed increased anxiety-like behavior, which was reduced by ventricular infusion of the CRF2 antagonist antisauvagine-30 (ASV 2μg/2μl). Surprisingly, ventricular ASV increased anxiety-like behavior in rats pre-treated with saline, but had an anxiolytic effect in un-treated rats. Western blots were performed to determine whether differences in CRF receptor densities could explain ASV-induced behavioral results. Saline pre-treated rats showed reduced CRF1 receptor expression in the lateral septum compared to amphetamine pre-treated and un-treated rats. Overall, these results suggest that central CRF2 antagonism reduces anxiety states during amphetamine withdrawal, and that behavioral effects may be dependent upon the balance of CRF1 and CRF2 receptor activity in anxiety-related regions.",
keywords = "Amygdala, Antisauvagine-30, Anxiety, Corticotropin-releasing factor, Lateral septum, Stress",
author = "Reinbold, {Emily D.} and Scholl, {Jamie L.} and Oliver, {Kathryn M.} and Watt, {Michael J.} and Forster, {Gina L.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.neures.2014.08.010",
language = "English (US)",
volume = "89",
pages = "37--43",
journal = "Neuroscience Research",
issn = "0168-0102",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Central CRF2 receptor antagonism reduces anxiety states during amphetamine withdrawal

AU - Reinbold, Emily D.

AU - Scholl, Jamie L.

AU - Oliver, Kathryn M.

AU - Watt, Michael J.

AU - Forster, Gina L.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Increased depressive and anxiety-like behaviors are exhibited by rats and humans during withdrawal from psychostimulants. Anxiety-like behaviors observed during amphetamine withdrawal are mediated by increased expression and activity of corticotropin releasing factor type 2 (CRF2) receptors in the dorsal raphe nucleus (dRN). Anxiety-like behavior of rats during withdrawal can be reversed by CRF2 receptor antagonism in the dRN, but the efficacy of global central CRF2 receptor antagonism is unknown. Rats were treated with amphetamine (2.5mg/kg, ip.) or saline daily for 2 weeks, and were tested for anxiety-like behaviors during withdrawal. Rats undergoing withdrawal showed increased anxiety-like behavior, which was reduced by ventricular infusion of the CRF2 antagonist antisauvagine-30 (ASV 2μg/2μl). Surprisingly, ventricular ASV increased anxiety-like behavior in rats pre-treated with saline, but had an anxiolytic effect in un-treated rats. Western blots were performed to determine whether differences in CRF receptor densities could explain ASV-induced behavioral results. Saline pre-treated rats showed reduced CRF1 receptor expression in the lateral septum compared to amphetamine pre-treated and un-treated rats. Overall, these results suggest that central CRF2 antagonism reduces anxiety states during amphetamine withdrawal, and that behavioral effects may be dependent upon the balance of CRF1 and CRF2 receptor activity in anxiety-related regions.

AB - Increased depressive and anxiety-like behaviors are exhibited by rats and humans during withdrawal from psychostimulants. Anxiety-like behaviors observed during amphetamine withdrawal are mediated by increased expression and activity of corticotropin releasing factor type 2 (CRF2) receptors in the dorsal raphe nucleus (dRN). Anxiety-like behavior of rats during withdrawal can be reversed by CRF2 receptor antagonism in the dRN, but the efficacy of global central CRF2 receptor antagonism is unknown. Rats were treated with amphetamine (2.5mg/kg, ip.) or saline daily for 2 weeks, and were tested for anxiety-like behaviors during withdrawal. Rats undergoing withdrawal showed increased anxiety-like behavior, which was reduced by ventricular infusion of the CRF2 antagonist antisauvagine-30 (ASV 2μg/2μl). Surprisingly, ventricular ASV increased anxiety-like behavior in rats pre-treated with saline, but had an anxiolytic effect in un-treated rats. Western blots were performed to determine whether differences in CRF receptor densities could explain ASV-induced behavioral results. Saline pre-treated rats showed reduced CRF1 receptor expression in the lateral septum compared to amphetamine pre-treated and un-treated rats. Overall, these results suggest that central CRF2 antagonism reduces anxiety states during amphetamine withdrawal, and that behavioral effects may be dependent upon the balance of CRF1 and CRF2 receptor activity in anxiety-related regions.

KW - Amygdala

KW - Antisauvagine-30

KW - Anxiety

KW - Corticotropin-releasing factor

KW - Lateral septum

KW - Stress

UR - http://www.scopus.com/inward/record.url?scp=84919423118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919423118&partnerID=8YFLogxK

U2 - 10.1016/j.neures.2014.08.010

DO - 10.1016/j.neures.2014.08.010

M3 - Article

C2 - 25205625

AN - SCOPUS:84919423118

VL - 89

SP - 37

EP - 43

JO - Neuroscience Research

JF - Neuroscience Research

SN - 0168-0102

ER -